Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial

Dolmat M, Lemes JBP, Johnson WT, Wilkinson EL, Yaksh TL, Bottini N, Shah NJ. Disease modifying biomaterials for modulating mechanical allodynia in a preclinical model[...]

Thaweethai T, Donohue SE, Martin JN, Hornig M, Mosier JM, Shinnick DJ, Ashktorab H, Atieh O, Blomkalns A, Brim H, Chen Y, Cortez MM, Erdmann[...]

Oyeyemi DM, Ikesu R, Saliba D, Walling AM, Essien UR, Norris KC, Klomhaus A, Xu H, Gotanda H, Tsugawa Y. End-of-Life Care for Older Adults[...]